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Background: The aim of this study was to evaluate clinico-pathologic specific predictors of recurrence for stage
II/III disease. Improving recurrence prediction for resected stage II/III colon cancer patients could alter surveillance
strategies, providing opportunities for more informed use of chemotherapy for high risk individuals.
Methods: 871 stage II and 265 stage III patients with colon cancers were included. Features studied included
surgery date, age, gender, chemotherapy, tumor location, number of positive lymph nodes, tumor differentiation,
and lymphovascular and perineural invasion. Time to recurrence was evaluated, using Cox’s proportional hazards
models. The predictive ability of the multivariable models was evaluated using the concordance (c) index.
Results: For stage II cancer patients, estimated recurrence-free survival rates at one, three, five, and seven years
following surgery were 98%, 92%, 90%, and 89%. Only T stage was significantly associated with recurrence.
Estimated recurrence-free survival rates for stage III patients at one, three, five, and seven years following surgery
were 94%, 78%, 70%, and 66%. Higher recurrence rates were seen in patients who didn’t receive chemotherapy
(p = 0.023), with a higher number of positive nodes (p < 0.001). The c-index for the stage II model was 0.55 and 0.68
for stage III.
Conclusions: Current clinic-pathologic information is inadequate for prediction of colon cancer recurrence after
resection for stage II and IIII patients. Identification and clinical use of molecular markers to identify the earlier stage
II and III colon cancer patients at elevated risk of recurrence are needed to improve prognostication of early stage
colon cancers.
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Colorectal cancer represents the most commonly diag-
nosed gastrointestinal cancer and the third most common
cause of cancer-related death in the United States [1]. The
current TNM staging system for colorectal cancer is based
on three elements: the penetration of tumor into the intes-
tinal wall (T), the number of positive lymph nodes present
(N), and the presence of metastasis (M). For patients with-
out metastatic disease, surgery offers the only curative op-
tion. Chemotherapy is largely reserved for patients with* Correspondence: tsikitis@ohsu.edu
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unless otherwise stated.positive lymph nodes (stage III disease) [2], because it can
reduce the risk of disease recurrence by 40 to 50%.
Clinicians do not currently question the benefit of
chemotherapy for stage III colon cancer patients, des-
pite the fact that 50% of these patients will eventually
develop metastatic disease. Results of the Quick and
Simple and Reliable (QUASAR) study implied that cer-
tain patients with stage II colon cancer (T3, T4/N0)
may have more favorable outcomes with adjuvant therapy
[3]. Despite being controversial, chemotherapy for stage II
disease is advised for patients with poor prognostic factors
including T4 stage, less than 12 lymph nodes sampled at
the time of resection, clinical bowel obstruction and per-
foration, and poor histologic grade with lymphovascular
and perineural invasion [3,4]. The predictive accuracy
of those clinico-pathologic characteristics has not beenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cer. In this study, we aimed to examine the performance
of those clinical predictors of recurrence-free survival
for stage II and III colon cancer patients who were
treated in our institution.
Methods
Patient selection
Eight hundred seventy-one patients with stage II colon
cancer treated surgically between 1995 and 2007 and 265
patients with stage III colon cancer treated surgically be-
tween 1996 and 2001 were available for study. All patients
had signed consent to be included in the study, and the
appropriate approval from the Mayo Clinic Institutional
Review Board (IRB) had been obtained.
Clinical and pathologic features
The clinical and pathologic features studied for patients
with stage II colon cancer included year of surgery, age
at surgery, sex, adjuvant chemotherapy, tumor location,
primary tumor size, primary tumor classification, the
total number of lymph nodes examined, and tumor dif-
ferentiation. The clinical and pathologic features studied
for patients with stage III colon cancer included year of
surgery, age at surgery, sex, adjuvant chemotherapy,
tumor location, primary tumor size, primary tumor clas-
sification, regional lymph node involvement, the num-
bers of positive, negative, and total lymph nodes; tumor
differentiation, lymphovascular invasion, and perineural
invasion.
Follow-up and recurrence of disease
We included all recurrences in this patient population,
both local (anastomotic and regional) and distant (hepatic
and lung metastases). The follow-up included a colon-
oscopy one year after surgery, with a yearly CT of the
abdomen and pelvis every year for stage II and III
disease, for up to five years. The frequency of repeat
colonoscopies depended on the findings of the first sur-
veillance colonoscopy. Patients with normal exam had a
repeat colonoscopy three years later. Chest examination
consisted of a chest x-ray, though current NCCN guide-
lines call for a chest CT. The patients were primarily
followed by either their medical oncologists or a colo-
rectal surgeon within our institution. As our institution
is a large tertiary referral center, a high number of pa-
tients elected to be surveyed by local physicians. Those
patients have been excluded due to lack of data for
follow-up. In our study, we have included only patients
who had recurrences either reported at their six-month
surveillance visit or at a later date. The follow-up period
for this cohort of patients by our institutions’ oncology
team ranged up to ten years. There is a comprehensive
multidisciplinary approach for all cancer patients andsurveillance after colon cancer surgery is primarily car-
ried by our medical oncologists. The recurrences we
reported are not second primaries; these patients are
followed closely, as our institution is part of the National
Cancer Database sites.
Statistical methods
Continuous features were summarized with means, stand-
ard deviations (SD), medians, and ranges. Categorical
features were summarized with frequency counts and
percentages. Changes in features by year of surgery were
evaluated, using Spearman rank correlation coefficients,
Kruskal-Wallis and Wilcoxon rank sum tests, and chi-
square tests. Recurrence-free survival rates were esti-
mated, using the Kaplan-Meier method. Associations of
the features studied with time to recurrence were evalu-
ated, using Cox proportional hazards regression models
and summarized with hazard ratios and 95% confidence
intervals (CIs). Multivariable models were developed,
using stepwise selection with a significance level for a
feature to enter or leave the model of 0.05. The predict-
ive ability of the features in a model was evaluated,
using the c (for concordance) index proposed by Harrell
et al. [5]. The interpretation of the c-index is identical
to the interpretation of the area under a receiver operating
characteristic curve. A c-index of 1.0 indicates that the
features in the model perfectly separate patients with
different outcomes, while a value of 0.5 indicates that
the features contain prognostic information equal to
that obtained by chance alone. Statistical analyses were
performed, using the SAS software package (SAS Institute,
Cary, NC). All tests were two-sided and p-values <0.05
were considered statistically significant.
Results
Stage II
Clinical and pathologic features for the 871 patients with
stage II colon cancer are summarized in Table 1. The total
number of lymph nodes retrieved and examined was sig-
nificantly and positively correlated with year of surgery
(Spearman rank correlation coefficient 0.37; p < 0.001).
For example, the mean number of total lymph nodes for
patients treated between 1995 and 2001 was 14.1, which
increased to 20.5 for patients treated between 2002 and
2007 (p < 0.001). The distribution of tumor differentiation
also changed significantly over time. There were 42%,
50%, and 8% well, moderately, and poorly differentiated
tumors among patients treated between 1995 and 2001,
compared with 21%, 72%, and 7% well, moderately, and
poorly differentiated tumors among patients treated be-
tween 2002 and 2007 (p < 0.001).
At last follow-up, 87 patients experienced recurrence at
a mean of 2.3 years following surgery (median 1.9 years).
Among the 857 patients who did not experience a
Table 2 Univariate associations of clinical and pathologic
features with recurrence for 871 patients with stage II
colon cancer
Patient/Tumor characteristics Hazard ratio
(95% CI)
P-value
Year of surgery (1-year increase) 0.97 (0.92 – 1.04) 0.38
Age at surgery (10-year increase) 0.91 (0.76 – 1.08) 0.26
Sex
Female 1.0 (reference)
Male 1.20 (0.79 – 1.83) 0.40
Adjuvant chemotherapy†
No 1.0 (reference)
Yes 1.41 (0.87 – 2.27) 0.16
Tumor location
Right 1.0 (reference)
Sigmoid 1.37 (0.85 – 2.19) 0.20
Transverse 0.69 (0.32 – 1.53) 0.37
Left 0.58 (0.21 – 1.61) 0.30
Tumor location
Right, transverse, or left 1.0 (reference)
Sigmoid 1.50 (0.95 – 2.37) 0.08
Primary tumor size (20-mm increase)† 0.96 (0.80 – 1.15) 0.66
Primary tumor classification
T3 1.0 (reference)
T4 3.17 (1.79 – 5.61) <0.001
Total lymph nodes (10-node increase)† 0.84 (0.65 – 1.07) 0.15
Tumor differentiation†
Well 1.0 (reference)
Moderate 1.20 (0.76 – 1.89) 0.45
Poor 1.07 (0.44 – 2.59) 0.88
Tumor differentiation†
Well or moderate 1.0 (reference)
Poor 0.96 (0.42 – 2.20) 0.92
†Sample size for tumor size (N = 868), for total lymph nodes (N = 870), for
adjuvant chemotherapy (N = 847) and for tumor differentiation (N = 869).
Table 1 Summary of clinical and pathologic features for
871 patients with stage II colon cancer
Patient/Tumor characteristics
Age at surgery (years, mean ± SD) 71.1 ± 12.0
Primary tumor size (mm; mean ± SD)† 51.9 ± 22.8



















†Sample size for tumor size (N = 868), for total lymph nodes (N = 870), for
adjuvant chemotherapy (N = 847) and for tumor differentiation (N = 869).
Table 3 Estimated recurrence-free survival rates (95% CI;
number still at risk) by primary tumor classification for
871 patients with stage II colon cancer
Year T3 (N = 813) T4 (N = 58)
1 98% (97 – 99; 771) 95% (89 – 100; 51)
3 93% (91 – 95; 638) 79% (68 – 91; 36)
5 91% (89 – 93; 489) 72% (60 – 86; 23)
7 90% (88 – 92; 352) 72% (60 – 86; 19)
10 90% (87 – 92; 184) 72% (60 – 86; 11)
Tsikitis et al. BMC Cancer 2014, 14:336 Page 3 of 7
http://www.biomedcentral.com/1471-2407/14/336recurrence, the mean duration of follow-up was 7.0 years
(median 6.5 years). Estimated recurrence-free survival
rates (95% CI; number still at risk) at one, three, five,
seven, and ten years following surgery were 98% (97 – 99;
822), 92% (90 – 94; 674), 90% (88 – 92; 512), 89% (87 –
91; 371), and 89% (86 – 91; 195), respectively. Univariate
associations of the clinical and pathologic features studied
with recurrence are summarized in Table 2. Only primary
stage classification was significantly associated with re-
currence. Patients with T4 tumors were over three
times more likely to recur, compared with patients with
T3 tumors (hazard ratio (HR) 3.17; p < 0.001). The c-
index from this univariate model was 0.55. Estimated
recurrence-free survival rates by primary tumor classi-
fication are summarized in Table 3. Of note, after
adjusting for T stage (T4 versus T3), no other feature,
including chemotherapy, was statistically associated
with time to recurrence. Analyzing the data from the
total of 58 T4 patients in our cohort, six had missing
data regarding their chemotherapy; of the remaining
52, 26 (50%) were treated with % FU based chemother-
apy. In this subset, chemotherapy was not statistically
associated with time to recurrence (HR2.48; 95% CI
0.78-7.91; p = 0.12).Stage III
Clinical and pathologic features for the 265 patients with
stage III colon cancer are summarized in Table 4. The
number of negative lymph nodes and the total number of
lymph nodes examined were significantly and positively
Table 4 Summary of clinical and pathologic features for
265 patients with stage III
Patient/Tumor characteristic
Age at surgery (years, mean ± SD) 68.3 ± 12.5
Primary tumor size (mm; mean ± SD)† 47.2 ± 21.7
Positive lymph nodes (mean ± SD 2.3 ± 3.0
Negative lymph nodes (mean ± SD) 12.1 ± 8.3






























†Sample size for tumor size (N = 263), for tumor location (N = 259), for primary
tumor classification (N = 263) and for tumor differentiation (N = 264).
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coefficients of 0.22 and 0.22). None of the other features
studied changed significantly over time.
At last follow-up, 79 patients experienced recurrence
at a mean of 2.5 years following surgery (median
1.8 years). Among the 186 patients who did not experi-
ence a recurrence, the mean duration of follow-up was
5.4 years (median 5.1 years). Estimated recurrence-free
survival rates (95% CI; number still at risk) at one, three,
five, and seven years following surgery were 94% (91 –
97; 243), 78% (73 – 83; 187), 70% (65 – 77; 106), and66% (59 – 73; 55), respectively. Univariate associations
of the clinical and pathologic features studied with re-
currence are summarized in Table 5. The multivariable
model developed, using these features, is summarized in
Table 6. Patients treated with adjuvant chemotherapy
were significantly less likely to recur, compared with
those who were not treated (HR = 0.57; (0.35 – 0.93 95%
CI) p < 0.023). After adjusting for adjuvant chemother-
apy, each one-node increase in the number of positive
lymph nodes was associated with a 24% increased risk of
recurrence (HR = 1.24; (1.18 – 1.31 95% CI) p < 0.001).
Markedly, even after adjusting for the total lymph nodes,
which we recognize differed across patients, an increase in
the number of positive lymph nodes is still significantly as-
sociated with time to recurrence. The c-index from this
multivariable model was 0.68. Estimated recurrence-free
survival rates by primary tumor classification are summa-
rized in Table 7.
Discussion
The results of this study, analyzing the data of a total of
871 patients with stage II colon cancer, demonstrated a
five-year recurrence rate of 10%. Most recurrences oc-
curred in the first two years after surgery. The prognostic
factor identified was the T stage. The population of the
265 patients with stage III colon cancer had, as expected,
a much higher five-year recurrence rate of 30%, with most
recurrences occurring within the first two years after sur-
gery. The clinical prognostic factors for stage III colon
cancer included the number of positive lymph nodes and
the use of adjuvant chemotherapy.
Compared with other studies, the findings for risk of
recurrence for stage II and III colon cancer are similar
to those in our findings [6]. The 7th edition of the
American Joint Commission on Cancer (AJCC) [7] fur-
ther classified T4 stage II tumors into the sub categories
of T4a and T4b. This change was the result of observed
differences in outcomes within the T4 classification,
based on the tumor spread through the bowel wall either
to just serosa (T4a) or to adjacent organs (T4b). The
study that supported this finding examined 119,363
colon cancer patients from the Surveillance, Epidemi-
ology, and End Results (SEER) database and showed that
the survival rate of patients with stage IIB was lower
than those with stage IIIA. The authors attributed this
finding to the following factors: first, that patients with
stage III received adjuvant treatment and therefore fared
better than those with stage II disease that did not re-
ceive chemotherapy, and second, that patients with stage
T4 N1 tumors might have been understaged as stage T4
N0 tumors. The first argument has been challenged by
another study that had not shown statistically significant
differences in survival among patients with stage IIB and
IIIA disease [8]. To support the argument that patients
Table 5 Univariate associations of clinical and pathologic
features with recurrence for 265 patients with stage III
colon cancer
Patient and tumor characteristics Hazard ratio
(95% CI)
P-value
Year of surgery (1-year increase) 0.98 (0.86 – 1.11) 0.71
Age at surgery (10-year increase) 1.10 (0.91 – 1.33) 0.31
Sex
Female 1.0 (reference)
Male 1.16 (0.75 – 1.80) 0.51
Adjuvant chemotherapy
No 1.0 (reference)
Yes 0.68 (0.42 – 1.09) 0.11
Tumor location†
Right 1.0 (reference)
Sigmoid 0.82 (0.49 – 1.38) 0.46
Transverse 1.01 (0.50 – 2.03) 0.98
Left 0.78 (0.35 – 1.75) 0.55
Tumor location†
Right, transverse, or left 1.0 (reference)
Sigmoid 0.85 (0.52 – 1.39) 0.51
Primary tumor size (20-mm increase)† 1.16 (0.96 – 1.41) 0.12
Primary tumor classification
T1 1.0 (reference)
T2 3.70 (0.46 – 30.05) 0.22
T3 4.34 (0.60 – 31.34) 0.15
T4 9.59 (1.23 – 74.94) 0.031
Primary tumor classification†
T1, T2, or T3 1.0 (reference)
T4 2.35 (1.21 – 4.57) 0.012
Regional lymph node involvement
N1 1.0 (reference)
N2 3.23 (2.06 – 5.06) <0.001
Positive lymph nodes (1-node increase) 1.23 (1.17 – 1.30) <0.001
Negative lymph nodes (10-node increase) 1.04 (0.78 – 1.37) 0.80
Total lymph nodes (10-node increase) 1.34 (1.06 – 1.69) 0.013
Tumor differentiation†
Well 1.0 (reference)
Moderate 1.50 (0.89 – 2.52) 0.13
Poor 1.90 (0.86 – 4.17) 0.11
Tumor differentiation†
Well or moderate 1.0 (reference)
Poor 1.45 (0.72 – 2.90) 0.30
Lymphovascular invasion
No 1.0 (reference)
Yes 2.37 (0.95 – 5.89) 0.06
Table 5 Univariate associations of clinical and pathologic




Yes 0.99 (0.14 – 7.14) 0.99
†Sample size for tumor size (N=263), for tumor location (N=259), for primary
tumor classification (N=263) and for tumor differentiation (N=264).
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IIIA, a Dutch study that examined 2,282 patients with all
stages of colorectal cancer [9] demonstrated that patients
with stage IIB tumors had a higher risk of developing
locoregional recurrence when compared to patients with
stage IIIA.
None of the other factors, including total number of
lymph nodes, lymphovascular and perineural invasion,
and tumor differentiation or clinical obstruction at the
time of diagnosis were significantly associated with the
risk of recurrence for the patients with stage II colon
cancer. These findings differ from other studies demon-
strating that certain pathologic characteristics, such as
histologic grade, carry prognostic value. In particular, in
a study of 1,031 patients who underwent a curative re-
section for colon adenocarcinoma, tumor differentiation
was related to local recurrence with no events for patients
with well-differentiated tumors. In comparison, patients
with poorly differentiated tumors experienced a 6.8% risk
of local, regional, or distant recurrence [6].
The 7th edition of AJCC [7] emphasizes that at least
10–14 nodes should be retrieved in colon specimens for
adequate staging. In our study, the mean number of lymph
nodes was 16.5. Notably, the total number of lymph nodes
examined was positively correlated with year of surgery
(Spearman rank correlation coefficient 0.37; p < 0.001), an
increase from a mean of 14.1, between years 1995 and
2001, to a mean of 20.5 for patients treated between 2002
and 2007 (p < 0.001). This increase of total number re-
trieval, however, did not improve disease-free survival
rates for this 871 patient cohort. Studies focusing on stage
II disease suggest that patients with fewer total lymph
nodes retrieved at surgery fare worse than those who had
a high number of total nodes recovered and examined
[10,11]. This argument is founded on the potential ofTable 6 Multivariable model to predict recurrence for 265
patients with stage III colon cancer





Yes 0.57 (0.35 – 0.93) 0.023
Positive lymph nodes (1-node increase) 1.24 (1.18 – 1.31) <0.001
Table 7 Estimated recurrence-free survival rates (95% CI; number still at risk) by primary tumor classification for 265
patients with stage III colon cancer
Year T1 (N = 12) T2 (N = 27) T3 (N = 205) T4 (N = 19)
1 100% (100 – 100; 12) 100% (100 – 100; 26) 94% (90 – 97; 187) 89% (76 – 100; 16)
3 100% (100 – 100; 12) 80% (65 – 97; 19) 78% (72 – 84; 144) 61% (42 – 88; 10)
5 89% (71 – 100; 6) 73% (56 – 95; 11) 70% (63 – 77; 81) 55% (36 – 84; 7)
7 89% (71 – 100; 2) 73% (56 – 95; 7) 66% (59 – 74; 43) 38% (19 – 74; 3)
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tases, a finding that was not observed in our study.
Furthermore, a c-index of 0.55 indicates that we
cannot adequately predict recurrence for our stage II
colon cancer patients, using current clinico-pathological
features. It is difficult at this juncture to determine
why the number of lymph nodes retrieved per specimen
has increased, but acknowledge that the pathologic
techniques of lymph node retrieval have improved over
the years.
In stage III colon cancer, the increasing number of
positive lymph nodes present was a stronger indicator of
risk, as expected. It has been shown that after adjusting
for T stage, patients with N0 disease (0 positive lymph
nodes) have an expected 5-year survival rate of 86%,
compared to those with N2 disease (patients with >3
positive lymph nodes) with expected 5-year-survival rate
of 69% [12]. Our results show that, after adjusting for
adjuvant chemotherapy, each one-node increase in the
number of positive lymph nodes was associated with a
24% increased risk of recurrence (HR 1.24; (118 – 1.31
95% CI) p < 0.001), verifying that an increasing number
of positive lymph nodes is the most significant predictor
of recurrence.
As expected, adjuvant chemotherapy for the stage III
patients improved five-year disease-free survival rates, a
finding consistent with those from the randomized clinical
trials [2]. In a prognostic nomogram of all stages of colon
cancer [13], adjuvant chemotherapy negated the negative
prognostic factors of advanced T and N stage, and the
c-index was 0.77 in predicting relapse for all stages of
colon cancer. Although their reported c-index is prom-
ising, the model is driven by a larger proportion of stage
I and IIA patients in the cohort and not by the stage III
patients. Further, the published nomogram has not
been validated by other institutions. The c-index of our
multivariate model of the stage III colon cancer pa-
tients in our study was 0.70, much higher than the one
found for stage II (c-index 0.56), however, not ad-
equate. These findings illustrate the need to augment
the TNM system for identifying individuals at high risk
of recurrence.
A limitation of our study was the lack of follow-up of
carcineoembryonic antigen (CEA). The role of CEA after
surgical resection for colon cancer has been broadlyassessed and, in spite of its widespread use, its utility has
been controversial [14]. The argument in support of CEA
in follow-up is based on the fact that early detection of
asymptomatic recurrences is possible in patients with an
elevated CEA. Opponents of CEA testing argue that ap-
proximately 40% of all colorectal recurrences do not
demonstrate increased CEA levels [15], and no studies
have demonstrated improved quality of life with fre-
quent measurements. For these reasons, CEA measure-
ments were not part of the surveillance for our patient
cohort. Another limitation of our analysis was that all
procedures took place in a specialized tertiary center,
and the results may not be generalizable. In our institu-
tion, however, the fact that a group of specialized sur-
geons, medical oncologists and pathologists treated this
patient cohort reduces the effects of treatment hetero-
geneity that exist in cohort studies of this nature. We
are therefore better able to evaluate the independent
predictiveness of current clinic-pathologic factors separ-
ately for stage II and III disease.
Further, in our study, we did not include any molecular
markers of these tumors, including microsatellite instabil-
ity (MSI) status. Our primary aim was to examine clinical
and pathologic characteristics of stage II and III colon can-
cers, characteristics that are routinely obtained in commu-
nity and specialty practice settings. Molecular profiling of
colorectal tumors in the clinical setting carry great prom-
ise, but are not yet routinely performed as part of the
current standard of care in the management of early stage
colorectal cancers. For example, despite convincing evi-
dence that MSI is a promising molecular marker with
both prognostic and predictive value for chemosensitivity
[16,17], it is not routinely obtained.
Conclusions
In conclusion, colon cancer recurrence remains a
considerable problem. The TN system, combined with
all clinico-pathologic factors used today, fall short in
predicting relapse, particularly for stage II disease.
Identifying individual patients who might benefit from
adjuvant chemotherapy, particularly for the stage II
population is an unmet need. Integration of molecular
characteristics of the tumors may lead to the development
of a new staging system that will eventually surpass the
current TNM system.
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